The European Particle Therapy Network (EPTN) consensus on the follow-up of adult patients with brain and skull base tumours treated with photon or proton irradiation.

Brain tumour Central nervous system European Particle Therapy Network Follow-up Particle therapy Skull base tumour Toxicity

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
03 2022
Historique:
received: 01 10 2021
accepted: 19 01 2022
pubmed: 31 1 2022
medline: 8 4 2022
entrez: 30 1 2022
Statut: ppublish

Résumé

Treatment-related toxicity after irradiation of brain tumours has been underreported in the literature. Furthermore, there is considerable heterogeneity on how and when toxicity is evaluated. The aim of this European Particle Network (EPTN) collaborative project is to develop recommendations for uniform follow-up and toxicity scoring of adult brain tumour patients treated with radiotherapy. A Delphi method-based consensus was reached among 24 international radiation-oncology experts in the field of neuro-oncology concerning the toxicity endpoints, evaluation methods and time points. In this paper, we present a basic framework for consistent toxicity scoring and follow-up, using multiple levels of recommendation. Level I includes all recommendations that are considered minimum of care, whereas level II and III are optional evaluations in the advanced clinical or research setting, respectively. Per outcome domain, the clinical endpoints and evaluation methods per level are listed. Where relevant, the organ at risk threshold doses for recommended referral to specific organ specialists are defined. These consensus-based recommendations for follow-up will enable the collection of uniform toxicity data of brain tumour patients treated with radiotherapy. With adoptation of this standard, collaboration will be facilitated and we can further propel the research field of radiation-induced toxicities relevant for these patients. An online tool to implement this guideline in clinical practice is provided at www.cancerdata.org.

Identifiants

pubmed: 35093408
pii: S0167-8140(22)00021-4
doi: 10.1016/j.radonc.2022.01.018
pii:
doi:

Substances chimiques

Protons 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

241-249

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Laurien De Roeck (L)

KU Leuven, University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Belgium; University Hospitals Leuven, Department of Radiation Oncology, Belgium. Electronic address: Laurien.deroeck@uzleuven.be.

Hiska L van der Weide (HL)

Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands.

Daniëlle B P Eekers (DBP)

Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, The Netherlands.

Miranda C Kramer (MC)

Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands.

Claire Alapetite (C)

Institut Curie, Radiation Oncology Department, Paris & Proton Center, Orsay, France.

Malin Blomstrand (M)

Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Neil G Burnet (NG)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Valentin Calugaru (V)

Institute Curie, Paris, France; Institute Curie, Centre de Protonthérapie d'Orsay, Orsay, France.

Ida E M Coremans (IEM)

Leiden University Medical Centre, Department of Radiotherapy, The Netherlands; Holland Proton Therapy Centre, Delft, The Netherlands.

Dario Di Perri (D)

Department of Radiation Oncology, Cliniques universitaires Saint-Luc, Brussels, Belgium; Particle Therapy Interuniversitary Center Leuven (PartICLe), Belgium.

Semi Harrabi (S)

Heidelberg Ion-Beam Therapy Centre (HIT), Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.

Alberto Iannalfi (A)

National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.

Yvonne L B Klaver (YLB)

Holland Proton Therapy Centre, Delft, The Netherlands.

Johannes A Langendijk (JA)

Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands.

Alejandra Méndez Romero (AM)

Holland Proton Therapy Centre, Delft, The Netherlands; Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Frank Paulsen (F)

Department of Radiation Oncology, Eberhard-Karls-Universität Tübingen, Germany.

Erik Roelofs (E)

Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, The Netherlands.

Dirk de Ruysscher (D)

Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, The Netherlands.

Beate Timmermann (B)

Clinic for Particle Therapy, University Hospital Essen, West German Cancer Center (WTZ), Germany; West German Proton Therapy Center Essen (WPE), Germany; German Cancer Consortium (DKTK), partnersite Essen, Germany.

Pavel Vitek (P)

Proton Therapy Center Czech, Prague, Czech Republic.

Damien C Weber (DC)

Paul Scherrer Institut Center for Proton Therapy, ETH Domain, Villigen, Switzerland.

Gillian A Whitfield (GA)

The University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, United Kingdom; The Children's Brain Tumour Research Network, University of Manchester, Royal Manchester Children's Hospital, United Kingdom.

Petra Witt Nyström (PW)

Danish Centre for Particle Therapy, Aarhus, Denmark; Norwegian Radiation and Nuclear Safety Authority, Oslo, Norway.

Jaap Zindler (J)

Holland Proton Therapy Centre, Delft, The Netherlands; Haaglanden Medisch Centrum, Department of Radiotherapy, Leidschendam, The Netherlands.

Esther G C Troost (EGC)

German Cancer Consortium (DKTK), partnersite Essen, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Institute of Radiooncology - OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; National Center for Tumour Diseases (NCT), Partner Site Dresden, Germany.

Maarten Lambrecht (M)

KU Leuven, University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Belgium; University Hospitals Leuven, Department of Radiation Oncology, Belgium; Particle Therapy Interuniversitary Center Leuven (PartICLe), Belgium; Leuven Kanker Instituut (LKI), UZ Leuven Gasthuisberg, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH